Mylan Inc announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Clozapine tablets USP, 50 mg and 200 mg.

These additional strengths, which had US sales of approximately US$ 13.5 million for the 12 months ending December 31, 2009, according to IMS Health, complement Mylan's already approved and marketed strengths, which are therapeutically equivalent to Novartis' antipsychotic Clozaril 25 mg and 100 mg.

Currently, Mylan has 140 ANDAs pending US FDA approval representing US$ 98.3 billion in annual brand sales, according to IMS Health. Thirty-eight of these pending ANDAs are potential first-to-file opportunities, representing US$ 19.8 billion in annual brand sales, for the 12 months ending December 31, 2009, according to IMS Health.

Mylan ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories.